Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiniferatoxin - Sorrento Therapeutics

Next Previous
X
Search
Drug Profile

Resiniferatoxin - Sorrento Therapeutics

Alternative Names: MCP 101; RTX

Latest Information Update: 11 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • Phase I/II Cancer pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 08 Sep 2023 Efficacy and adverse events data from a phase IIa OAK trial in Pain released by Sorrento Therapeutics
  • 28 Apr 2023 Suspended - Phase-II for Cancer pain (Late-stage disease) in USA (Epidural)
  • 26 Sep 2022 Sorrento Therapeutics plans to conduct an end of phase II meeting with the FDA for the RTX program in Pain (osteoarthritis knee pain)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top